Helicobacter pylori Infection in Iran: A New Perspective

Amin Talebi Bezmin Abadi


With 22 deaths per day due to gastric cancer, Iran is certainly an attractive country for all kinds of research associated with H. pylori infection. Unfortunately, there are no reliable data on the virulence factors, vaccine and prevalence of the infection in Iran. Numerous anti-H. pylori therapies are available, although there is still no effective and ideal treatment in clinical settings. Currently, successful vaccine candidates are already examined in animal models, but have repeatedly failed upon attempts to translate the vaccine into humans. A national study with standard test, which can detect H. pylori infection among symptomatic and asymptomatic individuals, is necessary to find the actual prevalence of the infection in Iran. Current knowledge about prevalence, treatment and vaccines of H. pylori seems incomplete. Conclusively, it is worthwhile to note that H. pylori infection in developing countries such as Iran needs urgent reconsideration for all associated aspects.


Helicobacter pylori; Prevalence; Vaccines; Virulence; Iran

Full Text: PDF HTML


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.